CellsBin develops an AI-driven photonic semiconductor platform for rare cell detection, isolation, and characterization. This technology provides high detection sensitivity for profiling individual therapeutic cells, surpassing the limitations of flow cytometry and digital droplet PCR. The platform enables comprehensive analysis of rare cells to support cell therapy development and precision medicine applications.
Funding
$300K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AFPAFounders
Product
Problem
Current methods for mapping cell surface structures are time-consuming and lack the precision needed for effective development of targeted cell therapies. Inaccurate identification of tumor cells limits the efficacy of cancer treatments and hinders the creation of personalized therapies.
Solution
The company offers a biotech platform that combines generative artificial intelligence and advanced photonics to create detailed maps of cell surface structures. This platform enables researchers to precisely identify and characterize tumor cells, leading to the development of more effective and targeted cell therapies. By providing a high-resolution view of cell surfaces, the technology facilitates the discovery of novel biomarkers and therapeutic targets. The platform accelerates the development cycle for cell therapies, reducing the time and cost associated with traditional methods.
Target Audience
The primary target audience includes biotech companies, pharmaceutical researchers, and academic institutions involved in cell therapy development and cancer research.
Features
- Generative AI algorithms for predicting and modeling cell surface structures
- Advanced photonics technology for high-resolution imaging of cell surfaces
- Automated cell identification and characterization
- Integrated data analysis and visualization tools
- Customizable workflows for different cell types and applications